Cartesian Therapeutics, Inc.
RNAC
$12.33
-$0.48-3.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -81.16% | -109.18% | -94.09% | 537.17% | -1.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.16% | -109.18% | -94.09% | 537.17% | -1.65% |
| Cost of Revenue | 53.85% | -30.43% | -12.32% | -28.80% | -48.79% |
| Gross Profit | -267.06% | -51.08% | -70.72% | 265.83% | 70.85% |
| SG&A Expenses | -11.07% | -56.62% | -0.79% | 15.10% | 64.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.71% | -43.56% | -8.43% | -17.58% | -22.33% |
| Operating Income | -67.76% | 21.26% | -34.52% | 173.81% | 29.01% |
| Income Before Tax | 68.83% | 94.93% | -168.64% | 221.51% | -162.31% |
| Income Tax Expenses | -- | 101.51% | -- | -- | -- |
| Earnings from Continuing Operations | 68.83% | 94.23% | -168.64% | 221.51% | -162.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.83% | 94.23% | -168.64% | 221.51% | -162.31% |
| EBIT | -67.76% | 21.26% | -34.52% | 173.81% | 29.01% |
| EBITDA | -61.16% | 22.39% | -34.27% | 175.58% | 29.22% |
| EPS Basic | 93.49% | 99.01% | 35.44% | 125.86% | -147.65% |
| Normalized Basic EPS | 78.09% | 97.82% | 75.75% | 130.45% | 24.93% |
| EPS Diluted | 93.49% | 98.98% | 35.44% | 124.22% | -147.65% |
| Normalized Diluted EPS | 78.09% | 97.82% | 75.75% | 128.62% | 24.93% |
| Average Basic Shares Outstanding | 378.44% | 380.19% | 316.10% | 226.97% | 5.92% |
| Average Diluted Shares Outstanding | 378.44% | 380.19% | 316.10% | 247.84% | 5.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |